Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
March 03, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler safety profile
March 03, 2026 02:00 ET | Source: SNIPR BIOME

SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet Microbe

The Lancet Microbe publishes SNIPR001 Phase 1: safe, gut‑restricted, microbiome stable; Phase 1b HSCT trial >50% enrolled.
February 26, 2026 10:00 ET | Source: Curium

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...
February 26, 2026 07:00 ET | Source: AtaiBeckley N.V.

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

AtaiBeckley today announced topline results from its Phase 2a study evaluating EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder.
February 25, 2026 11:05 ET | Source: Longeveron

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Results of Phase 2b clinical trial demonstrating stem cell therapy improved condition of patients with aging frailty published in Cell Stem Cell journal.
February 25, 2026 04:00 ET | Source: SNS Insider pvt ltd

Pharmacovigilance Market Size to Reach USD 24.69 Billion by 2035 Owing to the Surging Demand for Drug Safety Monitoring Solutions Globally

Austin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Pharmacovigilance Market size is estimated at USD 8.91 billion in 2025 and is expected to reach USD 24.69 billion by 2035,...
February 21, 2026 06:00 ET | Source: Abivax

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at...
February 19, 2026 10:35 ET | Source: Herantis Pharma plc

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma...
February 06, 2026 08:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will...